OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO – Get Free Report)’s stock price crossed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $1.42 and traded as low as $1.28. OKYO Pharma shares last traded at $1.28, with a volume of 118,582 shares trading hands.
Analysts Set New Price Targets
OKYO has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of OKYO Pharma in a research report on Thursday, October 15th. HC Wainwright reaffirmed a “buy” rating on shares of OKYO Pharma in a report on Wednesday, October 7th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.67.
View Our Latest Stock Analysis on OKYO Pharma
OKYO Pharma Stock Down 10.5%
The stock has a fifty day simple moving average of $1.42 and a two-hundred day simple moving average of $1.60.
Institutional Inflows and Outflows
A hedge fund recently bought a new position in OKYO Pharma stock. Opaleye Management Inc. bought a new position in shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 375,204 shares of the company’s stock, valued at approximately $563,000. Opaleye Management Inc. owned approximately 0.71% of OKYO Pharma as of its most recent SEC filing. 2.97% of the stock is currently owned by hedge funds and other institutional investors.
OKYO Pharma Company Profile
OKYO Pharma Limited (NASDAQ:OKYO) is a clinical-stage biopharmaceutical company focused on developing precision medicines for inflammatory, ocular and pain-related diseases. The company’s research is centered on G protein-coupled receptors (GPCRs), a broad class of biological targets involved in regulating immune responses, pain signaling and other disease processes.
OKYO’s lead development program, OK-101, is a novel GPCR-targeting therapeutic being investigated for conditions including dry eye disease and neuropathic pain.
Recommended Stories
- Five stocks we like better than OKYO Pharma
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
